Archangels increases support for Scottish tech and life sciences companies in 2020

Despite the challenges of the Covid-19 pandemic, Edinburgh-based business angel investment syndicate, Archangels, led investments of GBP16.3 million in promising Scottish start-up and early stage companies in 2020, topping its 2019 total of GBP13.4 million by 22 per cent.

Across 2020, the syndicate directly invested GBP8.1 million (2019: GBP7.4 million) in companies in the tech and life sciences sectors and was lead investor on a total of 11 funding rounds.

 
Archangels has also appointed Maureen Kinsler to its board of directors.
 
Until her recent retirement from the post, Kinsler was Chair of Marks & Clerk, the international intellectual property service provider, which she joined in 2002. She is a UK and European patent attorney with extensive experience of patent prosecution, handling many internationally diverse patent portfolios for a range of clients. Kinsler specialises in photonics, semiconductors and computer related inventions.
 
Kinsler has a first-class honours degree in physics and a PhD in semiconductor devices from Glasgow University. She also has an MSc in intellectual property law from Queen Mary and Westfield College, University of London.
 
Archangels’ 2020 investments included funding for two new companies – GBP715,000 in Hearing Diagnostics, which has developed an innovative new system with the potential to revolutionise hearing tests globally, and GBP3.1 million in Integrated Graphene, which has developed a manufacturing process that enables it to produce high performing, pure, 3D graphene (3DG) foam directly onto any surface, at room temperature and in seconds.

Eric Young, Chairman of Archangels, says: “The Covid-19 pandemic didn’t stop our portfolio companies from continuing to innovate and Archangels was determined to provide the support that they, and our new investee companies, needed.
 
“I am particularly excited that Maureen Kinsler has agreed to join our board. Intellectual property is at the heart of each of our portfolio companies and I am confident that Maureen’s experience and expertise in this complex area will prove to be an invaluable asset for Archangels and our investee companies.”
 
Kinsler says: “Archangels has a proud tradition of supporting and growing technology and life science companies in Scotland.  I like what they stand for.  I am very much looking forward to working with the Board, the Executive team and our investee companies over the coming years to deliver sustainable growth in the Scottish market.”